volume 6, issue 1, P22-32 2015
DOI: 10.1007/s12668-015-0180-y
View full text
|
|
Share

Abstract: Abstract Rituximab, a monoclonal antibody against the CD20 molecule expressed on B cells, has revolutionized the treatment of B cell lymphomas. The use of rituximab significantly improves the long-term survival rates of lymphoma patients. However, there are still many patients who develop resistance to rituximab. Hence, the urgent need is enhancing the potency of anti-CD20 antibodies beyond that achieved with rituximab to provide effective therapies for more patients. Traditional studies about the killing mec…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
3
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals